Pfizer Inc. PFE announced that detailed results of phase III PALOMA-2 study evaluating the combination of its breast cancer drug Ibrance (palbociclib) and Novartis AG’s NVS Femara (letrozole) for the ...
The trial is unlikely to show a statistically significant improvement in invasive disease-free survival Pfizer’s bid to develop Ibrance (palbociclib) for a certain form of early breast cancer has hit ...
On Thursday, Pfizer Inc. (NYSE:PFE) and Alliance Foundation Trials, LLC (AFT) announced results from the Phase 3 PATINA trial. The trial demonstrated that the addition of IBRANCE (palbociclib) to ...
The FINANCIAL — Pfizer Inc. on September 16 announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending ...
Since its launch in 2015, it has been prescribed to more than 200,000 patients globally. The drug is currently approved for use in both men and women, expanding its market potential. Despite facing ...
Zacks Investment Research on MSN
What to expect from Pfizer's non-oncology business in Q4
Pfizer PFE is set to release its fourth-quarter and full-year 2025 results on Feb. 3, with investor attention focused on ...
Pfizer Inc. has a 6% yield and 8.49x P/E with new cancer drugs and GLP-1 therapies to offset 2026-2028 LOE cycles. Read why ...
Pfizer is a Buy at low valuation but faces a 2030 patent cliff, COVID sales declines, and LOE risks. Click here to read an analysis of PFE stock now.
Unele rezultate au fost ascunse, deoarece pot fi inaccesibile pentru dvs.
Afișați rezultatele inaccesibile